SCHEMBL3565496

SCHEMBL3565496

CN(C)CCOc1c(-c2ccccc2)n(S(=O)(=O)c2ccccc2)c2c(Cl)cc(Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.37
KDM4E B2RXH2 5/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CSF1R P07333 1/20 0.35
HTR7 P34969 2/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
HTR1F P30939 1/20 0.35
DRD3 P35462 1/20 0.35
MAPT P10636 1/20 0.34
ACLY P53396 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562676 0.96 HTR6 (0.39) HTR6KDM4ETDP1ALDH1A1CSF1R
SCHEMBL3561477 0.94 AGTR1 (0.39) HTR6KDM4ETDP1ALDH1A1CSF1R
SCHEMBL3559937 0.93 ACLY (0.37) HTR6KDM4ETDP1ALDH1A1CSF1R
SCHEMBL3563773 0.93 HTR6 (0.43) HTR6KDM4ETDP1ALDH1A1HTR7
SCHEMBL3562380 0.93 PSEN1 (0.35) HTR6KDM4ETDP1ALDH1A1CSF1R
SCHEMBL3558834 0.90 HTR6 (0.36) HTR6KDM4EALDH1A1CSF1RHTR7
SCHEMBL3562439 0.88 HTR6 (0.45) HTR6KDM4ETDP1ALDH1A1CSF1R
SCHEMBL3558884 0.88 HTR6 (0.38) HTR6KDM4ETDP1ALDH1A1CSF1R
SCHEMBL3563972 0.87 HTR6 (0.38) HTR6KDM4EALDH1A1NPSR1CSF1R
SCHEMBL3556312 0.86 KDM4E (0.36) HTR6KDM4EALDH1A1CSF1RHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP claimed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US claimed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US claimed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP claimed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO claimed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885KDM4E 3751/4885TDP1 2407/4885
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885KDM4E 3751/4885TDP1 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.